New therapeutic approaches with antibodies against IL‐5, IL‐4 or IL-13, which have been designed to target specific immune response pathways associated with eosinophilic esophagitis are currently not recommended in the guidelines of the American Gastroenterological Association Institute and the Joint Task Force on Allergy-Immunology Practice Parameters [74]. This evidence concerns the gene IL13 and eosinophilic esophagitis.